Does Cymbalta help OCD? (+3 alternatives)

In this article, we will discuss the effectiveness of Cymbalta in managing obsessive-compulsive disorder (OCD). We will also discuss the research studies suggesting the role of Cymbalta in managing the symptoms associated with OCD. Additionally, we will discuss the alternatives to Cymbalta if it fails to manage OCD in some individuals.

Does Cymbalta help OCD?

Yes, Cymbalta does help with obsessive-compulsive disorder (OCD). OCD is a mental disorder that is characterized by repetitive unwanted thoughts and behaviors. Cymbalta helps in the management of symptoms of OCD by increasing the levels of serotonin and norepinephrine in the brain. The elevated levels of these neurotransmitters help in the regulation of anxiety and obsessive thoughts associated with this condition.

Cymbalta is commonly known as duloxetine, which is an antidepressant medication. It is a drug of choice for managing various health conditions including depression, anxiety, fibromyalgia, and OCD in some individuals. However, the choice of a specific medication is highly individualized, and the effectiveness of Cymbalta for a particular health condition can vary from person to person (1).

What is the dosage of Cymbalta for managing OCD?

Cymbalta is generally prescribed for managing OCD at a dosage of 120 mg for a duration of 3 to 12 months. The therapeutic benefits of Cymbalta for OCD may become noticeable within the initial 3 to 4 weeks of treatment, as symptoms gradually show improvement (2).

It is crucial for individuals undergoing treatment to adhere to the prescribed dosage and continue taking Cymbalta until complete remission of OCD symptoms is achieved.  

What does research suggest?

According to research findings, Cymbalta has demonstrated effectiveness in managing symptoms of obsessive-compulsive disorder (OCD). In a specific case involving a patient with drug-resistant OCD, discontinuation of the previous treatment was recommended, and the initiation of Cymbalta was advised.

Initial administration at a 60mg dose did not yield noticeable improvement. However, upon increasing the dosage to 120 mg, significant improvement in OCD symptoms was observed within 4 weeks. Importantly, the patient reported no adverse effects associated with the use of Cymbalta at this dosage (2).

In another study, the utilization of Cymbalta for the management of obsessive-compulsive disorder over a 4-month duration resulted in significant improvement in symptoms (3).

What to do if Cymbalta fails to manage OCD?

Medications like Cymbalta usually take a few weeks to show improvement in your symptoms. However, if your condition does not get better even after 3 to 4 weeks of treatment, you should communicate with your healthcare provider for a comprehensive evaluation of your treatment plan. They may assess your condition and determine the actual cause of treatment failure.

If the current dosage of Cymbalta is proving ineffective in addressing your symptoms, your healthcare provider may consider adjusting the dosage to better suit your individual needs. This personalized approach involves increasing the amount of Cymbalta prescribed to enhance its therapeutic impact on your specific condition. 

Your healthcare provider may recommend an alternative to Cymbalta if even the higher dosage of Cymbalta fails to manage the symptoms of OCD.

It is important to note that, while some improvements may be observed early in the course of treatment, the full therapeutic effect may take time to manifest, and discontinuing the medication early could compromise the overall success of the treatment.

What are the alternatives to Cymbalta for treating OCD?

If Cymbalta does not show improvement in OCD symptoms, healthcare providers may consider alternative medications. These alternatives may include:

Other serotonin and norepinephrine reuptake inhibitors: Other SNRIs used for the management of OCD and its associated symtoms may include, venlafaxine and desvenlafaxine.

Selective serotonin reuptake inhibitors: These medications are usually considered a first line of treatment for OCD. Examples of this class of drugs may include, fluoxetine, fluvoxamine, and sertraline.

Monoamine oxidase inhibitors: MAOIs like phenelzine or tranylcypromine may be considered in cases of treatment-resistant OCD, but they require careful monitoring of diet and interactions with other medications.

It’s essential to consult with a mental health professional to determine the most appropriate treatment tailored to your individual needs. The choice of medication depends on various factors, including the individual’s specific symptoms, medical history, and response to previous treatments.

 In my opinion, Cymbalta is an effective and favorable choice of medication for the management of obsessive-compulsive disorder, and it is commonly prescribed in clinical settings for individuals dealing with this condition.

Was this helpful?

Thanks for your feedback!



Dhaliwal JS, Spurling BC, Molla M. Duloxetine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31747213.


Luís Blay S, Black DW. A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007;9(3):234-5. doi: 10.4088/pcc.v09n0311c. PMID: 17632660; PMCID: PMC1911164. a


Dougherty DD, Corse AK, Chou T, Duffy A, Arulpragasam AR, Deckersbach T, Jenike MA, Keuthen NJ. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2015 Jan 30;18(2):pyu062. doi: 10.1093/ijnp/pyu062. PMID: 25637377; PMCID: PMC4368895.

Find a supportive therapist who can help with Depression.

Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.


AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site